Factor VIIa: On its own and loving it

Blood

Volumn 120, Issue 4, 2012, Pages 705-707

  Monroe, Dougald M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9A; PROTHROMBIN; THROMBIN;

BLOOD CLOTTING; DRUG EFFICACY; DRUG MEGADOSE; ENZYME ACTIVITY; HEMOPHILIA; IN VIVO STUDY; LOW DRUG DOSE; NOTE; PRIORITY JOURNAL;

EID: 84864424499     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-05-429654     Document Type: Note

References (9)

1. Shibeko AM, Woodle SA, Lee TK, Ovanesov MV. Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids. Blood. 2012;120(4):891-899.
2. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (novoseven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost. 1998;80(5):773-778. (Pubitemid 28521721)
3. Lusher JM, Roberts HR, Davignon G, et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIaa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa study group. Haemophilia. 1998;4(6):790-798.
4. van 't Veer C, Golden NJ, Mann KG. Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa. Blood. 2000;95(4):1330-1335.
5. Rao LV, Rapaport SI. Factor VIIa-catalyzed activation of factorXindependent of tissue factor: its possible significance for control of hemophilic bleeding by infused factor VIIa. Blood. 1990;75(5):1069-1073. (Pubitemid 20086811)
6. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997;99(3):542-547. (Pubitemid 27519853)
7. Parameswaran R, Shapiro AD, Gill JC, Kessler CM. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the hemophilia and thrombosis research society registry. Haemophilia. 2005;11(2):100-106. (Pubitemid 40468056)
8. Holmberg HL, Lauritzen B, Tranholm M, Ezban M. Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, APCC and FVIII in tail bleeding in hemophilic mice. J Thromb Haemost. 2009;7(9):1517-1522.
9. Ivanciu L, Toso R, Margaritis P, et al. A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia. Nat Biotechnol. 2011;29(11):1028-1033.